Proteomic technologies have emerged as an important addition to the genomic and antibody-based technologies for the diagnosis of cancer. Important technologies include 2-D gel electrophoresis, mass spectrometry, laser capture microdissection, detection of molecular markers of cancer and protein patterns. For clinical applications, the most likely technologies to be used widely are protein biochips. Application of these technologies to various cancers are described. Proteomic technologies have a potential in developing molecular diagnostics and markers for the early detection of cancer. However, information from various diagnostic technologies should be integrated to obtain the optimal information required for clinical management of a patient.
Introduction
Nucleic acid analysis of tissues is important and several methods have been described in a special report on molecular diagnostics (1). However, discovering the genetic sequence encoding a protein is not sufficient to predict the size or biological nature of a protein. Studies at the messenger RNA (mRNA) level can assess the expression profiles of transcripts but these analyses measure only the relative amount of an mRNA encoding a protein and not the actual amount of protein in a tissue. To address this area, several protein-based analysis technologies have been developed. The new proteomic-based approaches to molecular diagnostics are aimed at the identification and investigation of protein markers in the actual histologically defined cell populations that are immersed in heterogeneous diseased tissue. It is envisioned that these investigations will eventually lead to novel diagnostic, prognostic, or therapeutic markers that can be applied to monitor therapeutic toxicity or efficacy (2). This is particularly important in cancer research where posttranslational modifications of a protein can specifically lead to the disease.
Proteomic technologies are reviewed elsewhere (3) and those that are relevant to diagnostics are listed in Table 1 . Proteomics is playing an important role in the study of cancer (4) . Other articles in this issue describe proteomics of cancers of various organs. Technologies that are especially suitable for diagnosis of cancer are described here briefly along with their applications. ProteinChip technology is described in a separate article in this issue.
Genomic versus proteomic technologies for diagnosis
Prior to the resurgence of interest in proteomics, genomicbased diagnostics was considered to be a new development to complement antibody-based diagnostics and in some cases to offer a better alternative. There are now three approaches to molecular-based diagnostics for cancer: 1) Identification of novel genes associated with a particular type of cancer. The disadvantage is that it only provides information on predisposition.
2) The proteomic approach is to identify the most promising protein targets (tumor marker proteins). Proteomic technologies enable a more accurate characterization of molecular pathology of tumors, monitoring of effects of treatment, prognosis, and development of personalized medicines The limitation of this approach is that promising protein targets are only found in tissue, and not in blood.
3) Antibody-based detection systems are the most widely used for identifying tumor antigens. Although the reliability of these methods has improved with technological advances, the inherent potential for nonspecificity and cross reactivity in any immunological reaction warrants caution when interpreting these results. Measurement of cancer antibodies in blood has several advantages over other molecular diagnostic technologies, as cancerspecific antibodies are detectable prior to the detection of tumor marker proteins or palpable tumor. Antibody detection has been refined by advent of proteomic technologies.
Diagnosis is not merely detection of disease but has broader implications when conducted at molecular level. Information from various technologies should be integrated to obtain the optimal information required for clinical management of a patient.
Proteomic technologies for cancer diagnosis
The classical approaches in proteomics involve separating proteins by two-dimensional (2-D) gels and identify visualizing spots. Protein can be detected by Western blot or fluo-rescence detection methods. The proteins are then analyzed and characterized using mass spectrometry and its modification − Matrix-Assisted Laser Desorption Mass Spectrometry (MALDI-MS). Other methods used include capillary electrophoresis, high performance liquid chromatography (HPLC) and electrospray ionization (ESI). The most comprehensive source of information on proteomics is found in protein sequence databases. Currently 2-D gel electrophoresis patterns are scanned into a computer and are then analyzed by computer algorithms that quantify the gel patterns according to whether they are obtained under normal or physiologically altered conditions.
MALDI-TOF Mass Spectrometry
Matrix Assisted Laser Desorption Ionization Time of Flight (MALDI-TOF) MS overcomes the rate-limiting step of the traditional mutation detection systems that require either radioactive, fluorescent or gel-based fragment detection and are limited in their speed and throughput. This approach separates and characterizes DNA and other molecules according to their mass: the fragment length does not limit charge ratio and the detection rate. Instead, MALDI-TOF works on the principle that each of the four DNA bases has its own signature mass: charge ratio and can, therefore, be identified as such. Each DNA sequence has its own unique mass and charge as determined by its base composition. Prepared samples form a matrix on a suitable carrier with light-absorbing crystals. The matrix is illuminated with a laser causing a small amount of sample to vaporize. An electrical pulse is applied to the flight tube upon launch and the 'time of flight' of the molecule is recorded with smaller molecules flying at a faster rate.
A model system for studying chemoresistance in human melanoma cells (MeWo) has been established utilizing the four commonly used cytotoxic drugs vindesine, cisplatin, fotemustine and etoposide to yield stable drug-resistant sublines. Phenotypical differences between MeWo cells and their chemoresistant counterparts have been analyzed by using 2-D gel electrophoresis. In one study, proteins that were overexpressed in chemoresistant cell lines were purified and identified using MALDI-TOF-MS and microsequencing and four proteins − the translationally controlled tumor protein, the human elongation factor 1-delta, tetratricopeptide repeat protein and the isoform 14-3-3-gamma of the 14-3-3-family − were found to be overexpressed in chemoresistant melanoma cell lines (5).
Laser capture microdissection
Laser capture microdissection (LCM) provides an ideal method for extraction of cells from specimens in which the exact morphologies of both the captured cells and the sur- rounding tissue are preserved. LCM methods enable successful extraction of DNA, mRNA, and proteins from tissue fragments down to the single cell level. Selected cells are retrieved by activation of a transfer film placed in contact with a tissue section and use of a laser beam that is focused on a selected area of tissue through an inverted microscope. The laser bonds the film to the tissue beneath it and these cells are then lifted free of surrounding tissue. PixCell II LCM system was initially conceived at the US National Institutes of Health and commercially developed by Arcturus Engineering Inc (Mountain View, California). It can locate a single cell or a group of cells in minutes and extracts them for molecular analysis using a simple aim-and-shoot method. It uses a low power infrared excitation to eliminate sample photo-degradation. Applications of LCM with proteomics have been described elsewhere (6). The diagnostic uses of LCM in combination with proteomics include genetic fingerprinting of malignant neoplasms and diagnosis of premalignant lesions.
Detection of molecular markers of cancer
Any specific molecular alteration of a cancer cell either on DNA, RNA, or protein level can be referred to as a molecular marker. The expression of a distinct gene can enable its identification in a tissue with none of the surrounding cells expressing the specific marker. Most tumor markers in current use were identified from protein-based approaches. Proteomics approach has been used to identify novel biomarkers (7).
Several cancer biomarker studies have been conducted using 2-D gel electrophoresis (8). Major advantages of cancer marker identification are the ability to profile tumor tissue and uncover a variety of markers: overexpressed proteins, posttranslational modified proteins, translocated proteins and cleavage products.
One of the hallmarks of an ideal tumor marker is that it is produced by the tumor but is not detectable in normal tissue. An example of the application of proteomics for detection of tumor markers is the identification of a novel variant alphafetoprotein -a blood-borne tumor marker with greatly improved specificity for diagnosis of primary liver cancer (9). Proteomic techniques have been used to systematically identify the proteins in urine samples of patients with squamous cell carcinoma of the bladder, identifying a protein called psoriacin as an early marker for the disease (10).
Efforts are underway in several laboratories to identify the genes encoding proteins that are overexpressed in tumors. The experimental evidence supporting a role for nuclear matrix governed regulatory control over gene expression, as well as the demonstration of tissue or cell type specific expression of some nuclear matrix proteins, led to the search for tumor specific nuclear matrix proteins.
Studies of global protein expression in human tumors have led to the identification of various polypeptide markers, potentially useful as diagnostic tools. Many changes in gene expression recorded between benign and malignant human tumors are due to post-translational modifications, not detected by analyses of RNA. Proteome analyses have also yielded information about tumor heterogeneity and the degree of relatedness between primary tumors and their metastases. Such information has been used to create artificial learning models for tumor classification. Hierarchical clustering analysis is a useful approach for analysis of protein profiles and show that this approach can be used for differential diagnosis of ovarian carcinomas and borderline tumors (11).
Nuclear matrix proteins
The nuclear matrix is the nonchromatin protein and ribonucleoprotein network that is left in the nucleus following the removal of membrane, cytoskeletal, and chromatin elements. Among the best-characterized nuclear matrix proteins (NMPs) are the lamins A, B, and C, which define the nuclear membrane. These proteins comprise part of what is known as the peripheral nuclear matrix. Two internal nuclear matrix proteins have been well characterized: nuclear mitotic spindle apparatus protein (NuMA) and the DNA relaxing enzyme topoisomerase II. Both proteins are found on the matrix in interphase cells and relocate to the chromosomes during mitosis. Antibodies have been used to identify and provide partial characterization of several nuclear matrix proteins. Evidence for cell types-specific expression of nuclear matrix proteins was obtained by the use of 2-D gel electrophoresis. Tumor-associated or tumor-specific polypeptides have been observed in several cancers in the human, using 2-D gel electrophoresis methods to compare nuclear matrix proteins derived from either tissue or cell lines displaying neoplastic or normal phenotypes. Use of NMPs as tumor markers is in development by Matritech Inc (Newton, MA).
Tumor specific or tumor-associated nuclear matrix proteins have been identified in human bladder carcinomas and the NMP22 Test Kit is now marketed for management and screening of individuals at risk of bladder cancer. Although urine cytology and cystoscopy are still the standard of practice, many candidate biomarkers for bladder carcinoma are emerging and being adopted into clinical practice. It is possible that using the current biomarkers as an adjuvant modality will improve our ability to diagnose and monitor bladder cancer (12).
Protein patterns
Diagnostic use of markers is now well known but protein patterns offer better diagnostic possibilities than a single biomarker. By this approach, the pattern itself, independent of the identity of the proteins or peptides, is the discriminator, and might represent a new diagnostic paradigm. A recent study from the National Cancer Institute (Bethesda, MD) showed that a new method of assessing protein patterns in blood samples has 100% sensitivity and 95% specificity (13). The study was conducted in two stages. First, protein patterns from the blood samples of women with known ovarian cancer and women without disease were generated using mass spectrometry, creating more than 15,000 data points per patient. Proteome Quest (Correlogic Systems Inc), a bioinformatics tool, was utilized to analyze the data and identify a proteomic pattern that completely discriminated the cancer from non-cancer samples. In the second stage, the discovered pattern -essentially a computational disease "model'' -was used to classify the independent set of blinded patient blood samples.
Generation of the mass spectra requires only a small serum sample that could be obtained by fingerpick, and results are obtained in less than 30 minutes. Cost-effective, highthroughput screening is feasible. Samples can be applied to mass spectroscopy chips in the local laboratory and then transported to a central laboratory that houses the analytical software. The findings of this study justify a prospective study to assess this technology as a screening tool for a disease that has a 5-year survival of only about 35%. This concept of recognizing protein patterns to diagnose disease offers potential benefits beyond ovarian cancer. Serum proteomic pattern analysis might ultimately be applied in medical screening clinics as a supplement to diagnostic work-up and assessment. A negative value, if the sensitivity remains at 100% on further trials, could be used for reassurance, whereas a positive value might be sufficient to warrant further investigation.
Aptamer-based technology for protein signatures of cancer cells
Aptamers are used to detect the protein signatures of cells. This is based on the tendency of short DNA molecules (oligonucleotides) to fold into shapes that bind to specific proteins. The aptamer hugs its protein in the same way as an antibody embraces a specific antigen. The technology can be used with biochips. Aptamer technology may provide a method for monitoring protein changes in the blood that can echo the onset of carcinogenesis, for example in women with genetic risk of breast cancer associated with BRCA1 dysfunction.
The interaction of the zinc finger protein WT1 with RNA aptamers has been investigated using a quantitative binding assay, and the results have been compared to those from a previous study of the DNA binding properties of this protein (14) . Results indicate that a hairpin loop is a critical structural feature required for protein binding, and that some con-sensus nucleotides can be substituted provided proper base pairing of the stem of the hairpin loop is maintained.
Diagnosis of cancers of various organs
Proteomic technologies have been used for the study of biology of cancer of various organs as indicated in other publications in this issue. Some diagnostic applications arise out of the knowledge gained from these studies. This section will review the diagnostic applications of proteomics in various cancers.
Breast cancer
Proteomics has the refinement and sensitivity to find proteins that are either uniquely or differentially expressed between different cell types. The global divergence between normal and tumor breast cells can be identified by using proteomics and can facilitate the development of new approaches to breast cancer treatment and monitoring.
Proteomic analysis was used to demonstrate that a 28.3 kD serum protein, designated NMP66, could distinguish malignant disease from benign conditions and normal controls (15). NMP66 is now being evaluated as a potential biomarker for early breast cancer detection in large-scale clinical trials.
Nipple aspirate fluid (NAF) has been used for many years as a potential non-invasive method to identify markers for breast cancer risk or early detection. Scientists at the Tissue Proteomics Unit of the FDA are exploring the use of surface enhanced laser desorption and ionization time of flight (SELDI-TOF) mass spectrometry to identify patterns of proteins that might define a proteomic signature for breast cancer (16). They have presented data showing that SELDI analysis of NAF is rapid, reproducible, and capable of identifying protein signatures that appear to differentiate NAF samples from breast cancer patients and healthy controls, including those with an abnormal mammogram who were later proven to be biopsy normal.
Colorectal cancer
The early diagnosis of colorectal cancer and the early detection of recurrence are important for effective treatment. Efforts have been made to identify the existence of a specific NMP fingerprint for human colon cancer, using high-resolution, 2-D gel electrophoresis. Data provided by one study demonstrates that examination of the nuclear matrix composition allows differentiation of colon cancer tissue from normal adjacent and normal colon tissue (17). Development of an assay to detect these specific NMPs by examining tissue, serum, and stool specimens is a promising method for early detection of colorectal cancer.
Prostate cancer
Protein expression profiles of androgen-stimulated prostate cancer cells were generated by 2-D electrophoresis (18). Mass spectrometric analysis of androgen-regulated proteins in these cells identified the metastasis-suppressor gene NDKA/nm23, a finding that may explain a marked reduction in metastatic potential when these cells express a functional androgen receptor. Quantitation of the number of prostatespecific antigen molecules/cell was conducted on human prostate tissue cells by coupling of LCM with sensitive quantitative chemiluminescent immunoassays (19). This work was done at the NCI and NIH and the data is accessible at the web site (http://www.nci.nih.gov).
Specific populations of normal and malignant epithelium from radical prostatectomy tissue specimens procured LCM, have been analyzed by two-dimension polyacrylamide gel electrophoresis (2-D PAGE). The data demonstrate that 2-D PAGE analysis of LCM-derived cells can reliably detect alterations in protein expression associated with prostate cancer, and that these differentially expressed proteins are produced in high enough levels which could enable their clinical utility as serum markers and/or imaging markers (20) .
Esophageal cancer
Normal squamous epithelium and corresponding tumor cells from patients have been subjected to laser-capture microdissection and studied by 2D-PAGE (21). Comparison of the microdissected protein profiles showed a high degree of similarity between the matched normal-tumor samples (98% identical). However, 17 proteins showed specific-specific alterations, including 10 that were uniquely present in the tumors and seven that were observed only in the normal epithelium. Two of the altered proteins were characterized by mass spectrometry and immunoblot analysis and were identified as cytokeratin 1 and annexin I. This study shows that it is possible to obtain 2-D PAGE protein profiles, visualize disordered proteins, and subsequently determine of the identity of selected proteins by high-sensitivity MS microsequencing from microdissected cell populations.
Proteomics profiles in leukemia
Protein expression patterns obtained by 2-D gel electrophoresis were systematically compared and correlated with clinical features in human B-cell chronic lymphocytic leukemia in a pilot study (22) . This type of leukemia is characterized by broad clinical variability and morphological examination cannot differentiate between various subtypes. In this study, statistical methods were devised to analyze the spot pattern from 24 patient samples. This analysis enabled the identification of proteins that clearly discriminated between the patient groups with defined chromosomal characteristics or whose expression levels did correlate with clinical parameters such as patient survival. This study demonstrates that the correlation of large-scale protein expression profiles with clinical data can be used to gain new insights into molecular aspects of leukemia. The data showed that B-cell chronic lymphocytic leukemia patient populations with shorter survival times exhibit changed levels of redox enzymes, heat shock protein 27 and protein disulfide isomerase. These molecules may be potentially involved in drug resistance.
Antiannexins as tumor markers in lung cancer
Immune response manifested by annexins I and II autoantibodies occurs commonly in lung cancer and is associated with high circulating levels of IL-6 -an inflammatory cytokine. A proteomic approach using 2-D PAGE, followed by Western blot analysis in which individual sera were tested for primary antibodies has led to the discovery of antiannexins I and/or II in sera from patients with lung cancer (23). Markers have been detected in 90% of cases of lung adenocarcinoma. The CARET (Carotene and Retinol Efficacy Trial) feasibility study showed that anti-annexin antibodies could be detected in serum samples collected a year prior to clinical diagnosis of lung cancer.
Concluding remarks
Over the past decade, molecular profiling has emerged as a dynamic new discipline, capable of generating a global view of mRNA, protein patterns, and DNA alterations in various cell types and disease processes. Proteomic separation and analytical techniques are uniquely capable of detecting tumor-specific alterations in proteins. Proteomic technologies have a potential in developing molecular diagnostics and markers for the early detection of cancer. The findings will modify current pathological classifications and grading methods of cancer during the next decade. It is anticipated that the histological examination of biopsy sample of a tumor will be supplemented by biochip-based genomic, transcription and protein analysis to produce a unique tumor fingerprint. Proteomic technologies will have an impact on the diagnosis and management of cancer. For clinical applications, the most likely technologies to be used widely are protein biochips.
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